| Document |
Document Title |
|
WO/2024/079314A1 |
The invention relates to a dosage regimen, method for treating, delivery device or parenteral formulation for use in the treatment of a psychiatric or neurological disorder in a patient. In particular, the invention relates to the admini...
|
|
WO/2024/079647A1 |
The present invention relates to a composition comprising at least one psychedelic tryptamine, preferably derived from psychedelic psilocybin mushrooms, more preferably from psychedelic psilocybin mushrooms belonging to the Psilocybe gen...
|
|
WO/2024/079221A1 |
An isolated protein comprising (i) a first protein moiety selected from the group of proteins comprising an amino acid sequence having at least 70% identity to residues 113-231 of 5 Bri2 from human (SEQ ID NO: 2); and proteins comprising...
|
|
WO/2024/078607A1 |
Provided in the present invention are a pharmaceutical composition for treating Parkinson's disease and a preparation method therefor. Compared to the reference preparation "Xining", the carbidopa and levodopa sustained-release tablet pr...
|
|
WO/2024/077893A1 |
Disclosed in the present invention are preparation of a combination of stem cells and a hydrogel as a biomaterial, and the use of the combination in spinal cord injuries. The preparation comprises the following steps: preparing methacryl...
|
|
WO/2024/079351A1 |
The present invention relates to a compound of general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof. The invention further relates to the use of the compounds of the invention as neuroprotective and/or neurore...
|
|
WO/2024/081604A1 |
The present relates to polynucleotide constructs encoding an ApoE3 related protein optionally containing one or more intron. Potential uses of the different constructs include gene therapy targeting one or more disease or disorder, for e...
|
|
WO/2024/080768A1 |
The present invention relates to a pharmaceutical composition for preventing or treating peripheral neuropathy, and the like. The present invention has been completed by confirming that an isoquinoline derivative discovered through a scr...
|
|
WO/2024/081168A1 |
This disclosure relates to the field of therapeutic tyrosine kinase inhibitors, in particular Bruton tyrosine kinase ("BTK") inhibitors for treatment of subjects with relapsing multiple sclerosis.
|
|
WO/2024/081959A2 |
The present disclosure presents compositions and methods for improving the condition of a subject, including improving cognitive function and mood effects. The composition comprises a first polyphenol and at least one essential oil(s), w...
|
|
WO/2024/079471A1 |
A prebiotic oligosaccharide composition for use in reducing the level of ammonia. The composition comprises oligosaccharide compounds, for example galactooligosaccharide compounds, which includes: (a) at least 8 wt% Gal-(β1-3)-Gal-(β1-...
|
|
WO/2024/054973A3 |
This disclosure relates to [2-(l-methyl-lH-indol-3-yl)ethyl]dipropylazanium iodide (1- methyl-/V,/V-di-n-propyltryptammonium iodide or 1-Me-DPT iodide), crystalline 1-Me-DPT iodide, 2- (2-methyl-lH-indol-3-yl)ethan-l-aminium hydrogen oxa...
|
|
WO/2024/079682A1 |
The present invention relates to a sulfoximine compound having a novel structure, stereoisomers thereof or pharmaceutically acceptable salts thereof, and a use thereof for preventing or treating histone deacetylase-mediated diseases The ...
|
|
WO/2024/054545A3 |
This invention relates to compounds for the treatment of mild cognitive impairment and dementia. Previously, there was no single administration treatment intended to provide symptomatic relief of behavioral symptoms of Dementia with Lewy...
|
|
WO/2024/078488A1 |
Disclosed in the present invention are a thiochroman derivative and a preparation method therefor and a use thereof. The structure of the thiochroman derivative is as shown in general formula (I), and the definition of each substituent i...
|
|
WO/2024/079342A1 |
The present invention relates to new pyrrolopyrimidines and purines which surprisingly act as CSF-1R inhibitors, to processes for making these compounds, and to uses thereof.
|
|
WO/2024/078373A1 |
The present invention relates to a use of jojoba oil in preparation of e-liquid of an electronic cigarette. The jojoba oil is used as a solvent in the process of preparing the e-liquid of an electronic cigarette. The present invention ha...
|
|
WO/2024/081934A1 |
Described herein are methods and compositions for treating Alzheimer's Disease (AD), as well as compositions comprising a reelin-derived peptide and methods of use thereof.
|
|
WO/2024/080440A1 |
The purpose of the present invention is to provide a composition for preventing or treating neurodegenerative disorders, comprising humanin peptide as an active ingredient. When the humanin peptide of the present invention was administer...
|
|
WO/2024/080721A1 |
The present invention relates to methods for the treatment of proteinpathies, more especially, methods of i) preventing or reducing protein aggregation, ii) reducing protein deposition, iii) reducing cytotoxicity induced by protein aggre...
|
|
WO/2024/081442A1 |
Soluble proteins and extracellular vesicles (EVs) produced by optic nerve lamina region neural progenitor cells (ONLR-NPCs) are provided. Such proteins and EVs include growth factors and survival factors that can be used in the treatment...
|
|
WO/2024/081828A1 |
Neuropsychiatric treatments, including methods, regimens, and interventions to reduce physical dependence to those neuropsychiatric treatments based on ulotaront administration.
|
|
WO/2024/079128A1 |
The invention relates to compounds and their therapeutic use, said compounds having the formula (I): wherein, for example, Z is representing a (II) X is representing a NR5R6 group wherein R5 and R6 are hydrogen, R1 is represe...
|
|
WO/2024/080323A1 |
Provided is a novel use of a composition that contains a prescribed sulfur-containing compound, a salt thereof, or both. The present invention is a sirtuin activator or expression enhancer, a NAD+ increasing agent, or a senescent cell in...
|
|
WO/2024/081404A1 |
The present disclosure is related to dietary supplements including compositions that include, one or more agents that increase γ-aminobutyric acid (GABA) binding with GABA-A receptor, increase serotonin concentrations, decrease dopamine...
|
|
WO/2024/079645A1 |
The present invention relates to a composition comprising at least one psychedelic not phosphorylated tryptamine, preferably derived from psychedelic psilocybin mushrooms, more preferably derived from psychedelic psilocybin mushrooms bel...
|
|
WO/2024/077506A1 |
Atovaquone is used for treating and preventing acute and chronic inflammatory diseases in mammals, including mast cell-mediated inflammatory diseases.
|
|
WO/2024/079078A1 |
Disclosed are methods and compositions relating to antisense therapy for treating epilepsy, such as a focal epilepsy and temporal lobe epilepsy, in a subject in need thereof by targeting GRIK2 mRNA. In particular, the disclosure provides...
|
|
WO/2024/078124A1 |
Provided in the present invention is the use of a TDGF1 gene in the preparation of a drug for treating aging-related diseases or reversing cell aging. Compared with the prior art, the present invention has the following advantages: the u...
|
|
WO/2024/081554A2 |
Modified release tablet dosage forms comprising tolcapone are disclosed. The tablet dosage forms provide a pulsed, pH dependent release profile of tolcapone to both the gastric space and the small intestine. Methods of treating or preven...
|
|
WO/2024/079345A1 |
The present invention relates to new pyrrolopyrimidines and purines which surprisingly act as CSF-1R inhibitors, to processes for making these compounds, and to uses thereof.
|
|
WO/2024/055006A3 |
Disclosed herein, inter alia, are methods of treating pain by administering compositions that include at least one purified free amino acid, at least one purified fatty acid, and a purified fatty acid amide, related compositions, and kit...
|
|
WO/2024/078387A1 |
A substituted 3-fluorobenzenepropanoate compound represented by formula (I), an optical isomer thereof, a pharmaceutically acceptable salt thereof, a solvate (such as a hydrate) thereof, a clathrate thereof, a racemate thereof, a co-crys...
|
|
WO/2024/080708A1 |
The present invention relates to a pharmaceutical composition for the prevention or treatment of Parkinson's disease. Leading to the present invention, an isoquinoline derivative, identified through screening based on mitophagy activatio...
|
|
WO/2024/079291A1 |
The inventors have now succeeded in developing novel compounds comprising a diphenylpyrazole scaffold bearing amino side chains. These compounds have the advantage of repressing the production of Aβ1-x and modulating the ratio of autoph...
|
|
WO/2024/078517A1 |
A method of treating a glucose-6-phosphate dehydrogenase deregulated disorder in a subject in need thereof, the method involving administering a therapeutically effective amount of oleanolic acid or a conjugate salt thereof or prodrug th...
|
|
WO/2024/077355A1 |
The present disclosure relates to use of tear fluid neuropeptide Y (NPY) level for diagnosis, prognosis, assessment and therapy stratification of corneal nerve damage or loss, corneal neuropathy, corneal neuropathic pain, corneal neuralg...
|
|
WO/2024/080569A1 |
The present disclosure relates to a recombinant protein of beta-galactosidase-1 (GLB1) with a truncated C-terminus; a pharmaceutical composition for the treatment, prevention or amelioration of GM1 gangliosidosis or Morquio syndrome B,...
|
|
WO/2024/042226A3 |
A method for producing a purified morphinan-glycoside conjugate. The method includes the steps of contacting a morphinan compound with an activated saccharide or activated oligosaccharide and a glycosyltransferase in a reaction mixture u...
|
|
WO/2024/081718A1 |
The present disclosure provides methods for the treatment of migraine, such as the acute treatment of migraine, in particular during the prodrome stage of a migraine attack, comprising administering a CGRP receptor antagonist. In particu...
|
|
WO/2024/081932A1 |
Provided are methods for the treatment of spinal muscular atrophy (SMA) in a fetal subject in need thereof comprising administering an amount of risdiplam to a carrier of the fetal subject. Administering the amount of risdiplam to the ca...
|
|
WO/2024/056902A3 |
The disclosure features compositions and methods for the treatment of disorders associated with expression of wild-type or mutant Ataxin-2 (ATXN2) RNA transcripts, including disorders characterized by genes containing aberrantly expanded...
|
|
WO/2024/080843A1 |
The present application relates to a blood-brain barrier permeable fusion protein and use thereof, and provides: a blood-brain barrier permeable fusion protein comprising an IgG antibody, and a helical region binding moiety of transferri...
|
|
WO/2024/080661A1 |
The present invention relates to vMSC, which is a stem cell that is newly identified and has angiogenic properties. vMSCs cultured under specific culture conditions and identified, according to the present invention, are novel MSCs that ...
|
|
WO/2024/079317A1 |
The present invention relates to the treatment alpha-synucleinopathies. In this study, the inventors showed that restoring brain cholesterol pathway and defective autophagy by AAV- CYP46A1 delivery, as evidenced in several neurodegenerat...
|
|
WO/2024/077169A1 |
The present invention provides formulations of (R)-(1-(4-fluorophenyl)-6-((4-(trifluoromethyl)phenyl)sulfon
yl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-
yl)(pyridin-2-yl)methanone, and methods of making and using the same.
|
|
WO/2024/074850A1 |
The present invention is directed to the treatment of mental disorders. For example, there is provided a combination of a rapid-acting indolealkylamine and a mood preparation agent for use in a method for treating a mental disorder the m...
|
|
WO/2024/075825A1 |
The present invention addresses the problem of providing a novel compound that has an OX2R agonist activity. The present invention pertains to a cyclopentane compound represented by formula (I) or a pharmacologically acceptable salt th...
|
|
WO/2024/075736A1 |
The present invention addresses the problem of providing a nitrogen-containing compound effective for inhibiting cancer stem cell proliferation. The problem is solved by a nitrogen-containing compound represented by general formula (I)...
|
|
WO/2024/075145A1 |
The present invention relates to a human dental pulp-derived stem cell population and culture supernatant thereof, a pharmaceutical composition comprising the stem cell population, and method for producing same. Specifically, the present...
|
